byetta glp-1 diabetes market impact Agonists Weight Loss Drugs Report, 2025-2030 GLP-1 Antagonists Increase Plan Drug

In addition, they can be expensive and have side effects that reduce the overall quality of life and compliance of patients

Diabetologia 2016;59:426435 [DOI] [PMC free article] [PubMed] [Google Scholar] 42.MacConell L, Gurney K, Malloy J, Zhou M, Kolterman O

This raises questions about cost-effectiveness and access, but if priced reasonably or if generics eventually become available, we may see a broad shift where anti-obesity pharmacotherapy (especially GLP-1/GIP-based) is as commonplace as antihypertensive or lipid-lowering therapy

A.FallonM

However, both GLP-1-specific studies used laboratory conditions (animal models and cell cultures), not human clinical trials of oral supplementation